New probody immuno-oncology study for solid tumors

October 30, 2019 Providence News Team

Probody therapeutics are an emerging class of immuno-oncology therapies aimed at reducing the immune-related side effects associated with immune checkpoint inhibitors. A new multicohort study at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in the Robert W. Franz Cancer Center, tests the anticancer effects of an experimental probody therapeutic in patients with solid cancers:

CX-072 is a probody therapeutic directed against the programmed cell death ligand 1 (PD-L1) in the tumor microenvironment. By targeting the tumor microenvironment, CX-072 enhances the T-cell-mediated anticancer immune response while reducing immune-related side effects in healthy, peripheral tissues.

This phase II study will evaluate the clinical activity of CX-072 in combination with other anticancer therapies in four cohorts of adults with solid tumors:

  • Front-line therapy for patients with solid tumors who have received no prior therapy
  • Patients with progressive or relapsed solid tumors following PD-1/PD-L1 therapy
  • Patients with advanced/unresectable or metastatic disease following platinum-based therapy
  • Neoadjuvant therapy for patients with solid tumors who have received no prior therapy

prior study of CX-072 monotherapy showed anticancer activity and a favorable safety profile in patients with advanced or unresectable solid tumors.

For more information or to enroll a patient, call our Clinical Research office at 503-215-2614 or submit a referral form.

See more studies

New research studies are added frequently. Please visit our website to view studies for all cancer types currently open at Providence Cancer Institute.

About the Author

The Providence News Team brings you the updates to keep you informed about what's happening across the organizational ecosystem. From partnerships to new doctor announcements, we are committed to keeping you informed.

More Content by Providence News Team
Previous Article
Elsie Franz Finley: Agent of Change, Friend of Providence
Elsie Franz Finley: Agent of Change, Friend of Providence

In recognition of her decades of support, Providence Portland Medical Center has named the radiation oncolo...

Next Article
New studies offer novel therapies for patients with GI cancers
New studies offer novel therapies for patients with GI cancers

Cancer center offers several studies of targeted therapies, immunotherapies and combination therapies for p...